CellGenix Technologie Transfer GmbH

Development, manufacture and marketing of cell and protein therapeutics for tumour and orthopaedic patients, reagents for therapeutic ex vivo cell processing.

CellGenix Technologie Transfer GmbH is an innovative biopharmaceutical company headquartered in Freiburg, Germany. The company was founded in 1994 as a spin-off of University Hospital Freiburg. CellGenix owns Metreon Bioproducts GmbH, founded in 1996 as a joint venture with Schering AG. CellGenix also owns shares in American Fluoroseal Cooperation (Afc) in Gaithersburg, Maryland (USA) and in CellPrep S.A. in Buenos Aires (Argentina).

Felicia Rosenthal, MD, PhD, CEO
Stefan Thoma, PhD, Director Cellular Therapeutics
Bernd Leistler, PhD, Director Molecular and Ex Vivo Therapeutics
Gerd Steffens, PhD, Director Marketing & Sales Ex Therapeutics
Sönke Brunswieck, PhD, Director Marketing & Sales Ex Vivo Therapeutics
Michael Linse, Director Finance & Controlling
Juliane Müller, Human Resources

Georg Drischel, Dr. (Chairman)
Roland Mertelsmann, Prof. Dr.
Brandis, Prof. Dr.
Wilhelm Hellein, Dr.
Joachim-Friedrich Kapp, Dr.
Josef Walek, Dr.

Am Flughafen 16
79108 Freiburg
Germany
Phone: +49-761-88889-0
Fax: +49-761-88889-800

The company’s research is focused on stem cell therapy for the regeneration of tissues and organs, tumour immunotherapy and drug targeting. In addition, the company is developing IdioVax®, an innovative, patient-specific anti-lymphoma tumour vaccine and high-quality “kit systems” for the specific processing of cells for clinical cell therapy. The vaccine received EU-orphan drug status in 2004.

A patient-specific vaccine (IdioVax®) against lymph node cancer is in Phase II clinical trial

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.